HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook
Gilead Sciences Inc (NASDAQ:GILD) stock is trading higher on Thursday after the company reported better-than-expected ...
Yahoo Finance23d
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE ... of viral suppression (HIV-1 RNA <50 copies/mL) in virologically suppressed adults, a secondary endpoint of the ...
Business Wire24d
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral ...
There is currently no cure for HIV or AIDS. About Islatravir (MK-8591) and Merck’s HIV Research Islatravir (MK-8591) is Merck’s investigational nucleoside reverse transcriptase translocation ...
FierceBiotech23d
Merck-Gilead long-acting oral combo suppresses HIV for 48 weeks, setting stage for pivotal program
Gilead Sciences and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to sustained suppression of the virus out to 48 weeks in a ...
Merck tops earnings estimates on strong demand for Keytruda, new drugs even as HPV vaccine sales fall
The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...
The Columbian16h
Vancouver-based Absci marks major milestone in partnership with AstraZeneca on artificial intelligence-generated antibody
On the heels of releasing its latest financial statement, Vancouver-based biotechnology company Absci announced it has met its first milestone in its collaboration with pharmaceutical giant AstraZenec ...
Benzinga.com23d
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks
The data was presented at the ID Week 2024. At 48 weeks, the investigational combination maintained a high rate (n=49; 94.2%) of viral suppression (HIV-1 RNA <50 copies/mL) in virologically ...
pharmaphorum5d
FDA approves Merck’s Delstrigo and Pifeltro for HIV treatment
Merck, known as MSD outside the United States and Canada announced that the Food and Drug Administration (FDA) has approved two new HIV-1 medicines: Delstrigo and Pifeltro.
Business Insider24d
Gilead And Merck Report Phase 2 Results For Islatravir And Lenacapavir Combination In HIV Treatment
(RTTNews) - Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK ... a first-in-class HIV-1 capsid inhibitor. At 48 weeks, the novel investigational combination maintained a high rate of viral ...
A non-opioid pain med, a COVID-flu shot combo, and more: 7 drug launches to watch in 2025
As we start looking to the year ahead, the pharma industry is gearing up for a slate of new drug launches and U.S. Food and ...
MedPage Today28d
People With HIV Can Safely Receive Kidneys From Donors With HIV
"HIV-to-HIV transplantation is safe and saves ... the Infectious Diseases Society of America, Merck, Scynexis, Takeda, the United Network for Organ Sharing, UpToDate, AstraZeneca, the Cystic ...
Business Insider24d
Gilead, Merck announce from Phase 2 islatravir/lenacapavir combo study
Gilead Sciences (GILD) and Merck (MRK) announced new results from ... and lenacapavir, a first-in-class HIV-1 capsid inhibitor. These late-breaking data were presented during an oral session ...